Cagrilintide
Contents
What is Cagrilintide?
Cagrilintide is an investigational peptide that has gained attention for its potential role in appetite control and weight management. It is a long-acting analog of amylin, a hormone naturally released by the pancreas alongside insulin. While amylin has been known for decades to help regulate satiety and food intake, its short natural half-life limited its therapeutic usefulness. Cagrilintide was designed to overcome this limitation, offering prolonged activity and renewed interest in amylin-based treatments for obesity and metabolic disease.
What Is Amylin?
Amylin is a hormone secreted from the pancreas during meals. In fact, amylin and insulin are packaged together (in synaptic vesicles) and released with meals simultaneously. Amylin works in parallel with insulin to help regulate blood sugar and appetite. Amylin slows gastric emptying, suppresses excess glucagon release, and signals the brain to promote feelings of fullness. In people with obesity or type 2 diabetes, amylin signaling may be impaired, contributing to overeating and difficulty maintaining weight loss.
How Does Cagrilintide Work?
Cagrilintide binds to amylin receptors in the brain, particularly in areas involved in appetite regulation and satiety. By activating these pathways, it helps reduce hunger, increase feelings of fullness, and decrease overall caloric intake. Its long-acting design allows for sustained receptor activation, which may lead to more consistent appetite suppression compared to native amylin.
What is Cagrilintide Used for?
Cagrilintide is currently being studied primarily for:
- Chronic weight management
- Obesity-related metabolic conditions
- Adjunct therapy with GLP-1 agonists (retatrutide, tirzepatide, and semaglutide) to potentiate their effects
That said, human data is limited. Because BPC-157 is not FDA-approved, its long-term safety, ideal dosing, and full risk profile in humans are not yet fully understood.
Side Effects of Cagrilintide
The most commonly reported side effects of amylin-based therapies are gastrointestinal, including nausea and reduced appetite. These effects are generally dose-related and may lessen over time. Because cagrilintide is still investigational, long-term safety data is limited, and it is not yet approved for general clinical use.
Early studies suggest that amylin analogs like cagrilintide may help address weight-loss plateaus and improve long-term adherence by enhancing satiety without relying solely on appetite suppression.
- 1Weeks 1-4: 250 µg/day (0.25 mg/day)
- 2Weeks 5 and beyond: 500 µg/day (0.50 mg/day)
Cagrilintide Dosing Protocol (for Research)
Cagrilintide is effective, per research/educational protocols, when administered under the skin by injection (subcutaneous).
Independent researchers recommend combining cagrilintide with a GLP-1 agonist, such as semaglutide, tirzepatide, or retatrutide. When used in combination, it produces synergistic effects for weight loss and diabetes control.
Recommended research dosing protocol:
- 1Weeks 1–2: 0.6 mg/week
- 2Weeks 3–4: 1.2 mg/week
- 3Weeks 5–6: 2.4 mg/week
- 4Weeks 7 and beyond: 4.8 mg/week
Recommended Cagrilintide Source (for Research)